MONTREAL, /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...

BACKGROUND: Left ventricular hypertrophy (LVH) and prolonged QT interval at ECG (QTc) are common in both obesity and arterial hypertension (AH), and are risk factors for cardiovascular disease and ...

Please provide your email address to receive an email when new articles are posted on . Compared with married people, unmarried people were more likely to have a prolonged QT interval, according to ...

The QT interval is the time from the beginning of the QRS complex (ventricular depolarization) to the end of the T wave (ventricular repolarization). The normal QT interval is controversial and ...

As more consumer-facing devices add features to measure the heart’s electrical activity, companies are looking for new ways to turn this data into valuable health information. AliveCor, a startup that ...

LQT-1213 is a first-in-class serum glucocorticoid regulated kinase 1 inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LQT-1213, a first-in-class serum ...

(HealthDay News) — Use of a computerized clinical decision support system (CDSS) may reduce the risk of prolonged QT c interval in hospitalized patients at risk for torsades de pointes, according to ...

The use of intrathecal ziconotide to manage refractory malignant pain: Five case studies No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2009 ASCO Annual ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. COVID-19 infection is associated with a significant increase in the corrected QT interval (QTc) in ...

MONTREAL, Aug. 25, 2023 /PRNewswire/ - Thryv Therapeutics Inc. today announced positive results of the WAVE 1 Proof of Concept clinical study evaluating LQT-1213 for the reduction of QTcF in ...